Q4 2024 · 13F-HR
Samsara BioCapital, LLCholdings as filed
Filed 2025-02-14 · accession 0001104659-25-014316
$728.6M
Reported value
43
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $242.6M | 33.3% | 5,612,896 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $63.7M | 8.74% | 4,415,689 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $63.4M | 8.70% | 2,768,520 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $62.5M | 8.57% | 5,074,916 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $39.3M | 5.39% | 1,717,127 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $36.4M | 5.00% | 2,217,146 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $28.5M | 3.91% | 986,981 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $25.7M | 3.52% | 3,266,498 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $19.5M | 2.67% | 253,641 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $14.6M | 2.01% | 1,000,000 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $12.5M | 1.72% | 584,642 | Common | SOLE |
| G29687103 | AVDL | AVADEL PHARMACEUTICALS PLC | $10.2M | 1.40% | 967,527 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $9.7M | 1.33% | 172,647 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $9.4M | 1.29% | 3,768,035 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $8.6M | 1.18% | 588,816 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $8.2M | 1.12% | 679,486 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $7.9M | 1.09% | 2,523,022 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $7.1M | 0.97% | 824,155 | Common | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $7.0M | 0.96% | 2,442,352 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $6.2M | 0.85% | 850,000 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $5.9M | 0.81% | 2,385,060 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $5.5M | 0.76% | 6,130,268 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $4.7M | 0.64% | 2,609,114 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $4.5M | 0.62% | 97,625 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $4.3M | 0.59% | 1,562,500 | Common | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $4.0M | 0.55% | 2,196,814 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $2.9M | 0.40% | 291,666 | Common | SOLE |
| 918385204 | VTVT | VTV THERAPEUTICS INC | $2.9M | 0.39% | 206,784 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $1.9M | 0.27% | 630,000 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $1.9M | 0.26% | 147,319 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $1.4M | 0.19% | 198,000 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $1.2M | 0.16% | 405,228 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $1.1M | 0.15% | 202,348 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $827,249 | 0.11% | 399,637 | Common | SOLE |
| 231269309 | CRIS | CURIS INC | $606,541 | 0.08% | 198,216 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $603,021 | 0.08% | 11,263 | Common | SOLE |
| 097702104 | BOLT1EUR | BOLT BIOTHERAPEUTICS INC | $561,402 | 0.08% | 1,049,153 | Common | SOLE |
| 55234L105 | LYRAGBP | LYRA THERAPEUTICS INC | $405,718 | 0.06% | 1,965,689 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $208,228 | 0.03% | 172,089 | Common | SOLE |
| 50107A104 | KRON1USD | KRONOS BIO INC | $74,224 | 0.01% | 78,131 | Common | SOLE |
| 019818103 | — | ALLOVIR INC | $34,581 | 0.00% | 82,336 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $30,667 | 0.00% | 133,333 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $2,140 | 0.00% | 99,999 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.